News
MGNX
1.960
-1.01%
-0.020
Reported November 16, Roche Receives FDA Approval For Wiserdley In Combination With Everolimus For Breast Cancer Treatment
Benzinga · 3d ago
Leerink Partners Sticks to Their Buy Rating for MacroGenics (MGNX)
TipRanks · 4d ago
Weekly Report: what happened at MGNX last week (1109-1113)?
Weekly Report · 4d ago
MacroGenics Updates Corporate Presentation With Clinical Program Details
TipRanks · 11/13 22:48
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Thermo Fisher (TMO), MacroGenics (MGNX) and Diaceutics (OtherDIUXF)
TipRanks · 11/13 17:50
Stifel Nicolaus Sticks to Its Hold Rating for MacroGenics (MGNX)
TipRanks · 11/13 14:05
MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 11/12 21:25
*Macrogenics 3Q Rev $18.7M >MGNX
Dow Jones · 11/12 21:01
*Macrogenics 3Q Loss/Shr 32c >MGNX
Dow Jones · 11/12 21:01
Press Release: MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress
Dow Jones · 11/12 21:01
MacroGenics: Q3 Earnings Snapshot
Barchart · 11/12 15:16
Weekly Report: what happened at MGNX last week (1102-1106)?
Weekly Report · 11/09 10:19
Private Markets: Shield AI, Kalshi lead week’s biggest moves
TipRanks · 11/05 18:41
MacroGenics, Inc. Appoints Michael Vasconcelles and Emil Kuriakose to Board of Directors
NASDAQ · 11/04 04:38
MacroGenics Appoints Two Independent Directors to Board
TipRanks · 11/03 22:17
*MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Bd of Directors
Dow Jones · 11/03 21:14
Weekly Report: what happened at MGNX last week (1026-1030)?
Weekly Report · 11/02 10:18
Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals
NASDAQ · 10/30 16:56
MacroGenics Expands Solid Tumor Pipeline With New MGC030 Phase 1 Study
TipRanks · 10/30 16:30
MacroGenics Stock Tumbles as Patient Death, Severe Side Effects Cloud Cancer-Drug Data
Dow Jones · 10/26 16:44
More
Webull provides a variety of real-time MGNX stock news. You can receive the latest news about Macrogenics Inc through multiple platforms. This information may help you make smarter investment decisions.
About MGNX
MacroGenics, Inc. is a biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates from its proprietary suite of antibody technology platforms. It is developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which are referred to as DART and TRIDENT molecules). It has multiple proprietary product candidates. These include three clinical-stage ADCs incorporating a novel topoisomerase I inhibitor (TOP1i)-based linker-payload: MGC026, which targets B7-H3; MGC028, which targets ADAM9, and MGC030, which is directed against an undisclosed target. It is also developing lorigerlimab, a clinical-stage bispecific DART molecule targeting the immune checkpoint receptors PD-1 and CTLA-4. In addition, it is also developing multiple preclinical-stage ADC and next-generation T-cell engager programs.